The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
Research indicates that discontinuing GLP-1 medications around conception or in early pregnancy might carry risks. The study links stopping these drugs to increased gestational weight gain and adverse pregnancy outcomes. Experts emphasize the need for further investigation to fully understand the implications.
More and more fit individuals are turning to microdoses of GLP-1s, drawn by potential health benefits beyond weight loss. While some see it as a proactive approach to longevity, experts caution about the lack of research and potential risks.
New research indicates a connection between body composition and brain aging. The study suggests that individuals with more muscle mass and less hidden belly fat tend to have younger-appearing brains, as observed through MRI scans.
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
The global market for oral proteins and peptides is experiencing rapid expansion, with projections estimating a value of US$ 47.2 billion by 2035. This growth, driven by increasing demand for peptide-based therapeutics and advancements in delivery technologies, signifies a dynamic shift in the pharmaceutical and nutraceutical landscape.
The GLP-1 weight loss market is experiencing significant shifts with new leadership and competitive pressures. This article dives into the latest developments surrounding semaglutide, Ozempic, and Wegovy, and explores the broader impact on health and wellness.
New research shows that GLP-1 receptor agonists, often used for diabetes and weight loss, may reduce the risk of certain types of arthritis. This blog post explores the potential benefits of this peptide therapy, offering actionable insights for improved health and wellness.
New Wegovy trial results are making waves, showing impressive weight loss and cardiovascular benefits. Discover how GLP-1 therapies are transforming healthcare.
New data reveals a drop in US obesity rates, and GLP-1 drugs like Ozempic and Wegovy are likely playing a significant role. This post explores the impact of these medications and what it means for your health.
